ReviewJuntendo medical journal2025
The Possibility of DNA Methylation for Precision Medicine in Colorectal Cancer.
Review in Juntendo medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
I (the author) received the 44th Juntendo Medical School Alumni Association Academic Encouragement Award in May 2022. After graduating from Juntendo University School of Medicine in 2002, I trained in the Department of Coloproctological Surgery at Juntendo University, led by Professor Toshiki Kamano and Professor Kazuhiro Sakamoto. I then studied DNA methylation in cancer at Johns Hopkins University in Maryland in the United States of America from December 2013 to July 2016. I worked in the laboratory of Professor Malcolm V Brock, a thoracic surgeon, in the Department of Thoracic Surgery. The subject of this translational research was 'Epigenetics', and specifically DNA methylation in lung and esophageal cancer. Epigenetics is the study of potentially heritable changes in gene expression that do not involve changes to the underlying DNA sequence, while genetics involves changes to the underlying DNA sequence. In epigenetic alterations, methyl marks added to certain bases repress gene activity by tightly packing the chromatin. Recently, there have been many attempts to apply epigenetics to clinical diagnosis, treatment and prevention. Colorectal cancer is a global cause of death and an increasingly common disease worldwide. To predict and improve long-term outcomes in CRC, a wide variety of perioperative biomarkers, including imaging markers, blood markers, and pathological and molecular markers, have been reported as prognostic factors. This review includes a description of three of our previous studies on DNA methylation and summarizes the potential clinical usefulness of the findings in precision medicine for colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.